In February 2014, the EMCDDA and Europol examined the available information on a new psychoactive substance, 4-methyl-5-(4-methylphenyl)-4,5-dihydrooxazol-2-amine (commonly known by the abbreviation 4,4′-DMAR). The two organisations concluded that sufficient information had been accumulated to merit the production of a Joint Report on 4,4′-DMAR as stipulated by Article 5.1 of the Council Decision.
Table of contents
Introduction
Information collection process
Information required by Article 5.2 of the Council Decision
Information from the EMA as requested by Article 5.3 of the Council Decision
Conclusion
References
Annexes